Evidence map›Paper›PMID 32249667›Full record

ArticlemAbs

A rapid method for relative quantification of

Zaneer Segu, Todd Stone, Claudia Berdugo, Anthony Roberts, Emma Doud, Yunsong Li

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. AsymmetricJournal of the American Chemical Society · 2024
    Article
  5. Article
  6. Constant domain polymorphisms influence monoclonal antibody stability and dynamics.Protein science : a publication of the Protein Society · 2023
    Article
  7. High-Throughput Glycomic Methods.Chemical reviews · 2022
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zaneer SeguProcess Development, Catalent Biologics, Bloomington, IN, USA.
Todd StoneProcess Development, Catalent Biologics, Bloomington, IN, USA.ORCID 0000-0001-9895-4651
Claudia BerdugoProcess Development, Catalent Biologics, Bloomington, IN, USA.
Anthony RobertsProcess Development, Catalent Biologics, Bloomington, IN, USA.
Emma Doud
Yunsong LiProcess Development, Catalent Biologics, Bloomington, IN, USA.
Catalent (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylation is a common post-translational modification and critical quality attribute that can modulate the efficacy of therapeutic proteins. In the production of monoclonal antibodies (mAbs), quantifying the glycoform profile is a vital characterization step. Traditional glycan analysis is time consuming and involves steps at extreme temperature or pH, which may alter glycans. Here, we describe a rapid method for glycan analysis in which glycans are released from mAb samples that are bound to protein A columns. Since host cell proteins, which may also contain glycans, were already removed, this step enables analysis of cell culture products. Glycans released from the mAb samples are then derivatized with InstantPC™ labeling agent and analyzed by HILIC-FLD-MS. To illustrate the method, the glycan profiles of six trastuzumab (Herceptin®) antibody lots and four biosimilar developmental lots were analyzed. The results derived from our novel method, which takes less than 90 min, are compared with those from a typical glycan preparation approach.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsChromatography, LiquidGlycosylationHumansMass SpectrometryPolysaccharidesReproducibility of ResultsTrastuzumabAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsPolysaccharidesTrastuzumab2-aminobenzamide (2-AB) labelbiosimilarFc-containing proteinsglycoproteinherceptin antibodyhydrophilic interaction liquid chromatography (HILIC)IgGInstantPC labeling agent (IPC)monoclonal antibody (mAb)N-glycansprotein A (PA)trastuzumab

Identifiers

PMID32249667
PMCPMC7188402
OpenAlexW3014719656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.